Survival in medically treated patients with homozygous ゲ-thalassemia

New England Journal of Medicine

Volumn 331, Issue 9, 1994, Pages 574-578

  Olivieri, Nancy F ^a,b   Nathan, David G ^c   MaCmillan, James H ^a   Wayne, Alan S ^c   Liu, Peter P ^b   McGee, Allison ^a   Martin, Marie ^d   Koren, Gideon ^a   Cohen, Alan R ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DEFEROXAMINE; FERRITIN; INOTROPIC AGENT;

ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; FEMALE; FERRITIN BLOOD LEVEL; HEART DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; FEMALE; FERRITINS; HUMANS; IRON; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 0028086414     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199409013310903     Document Type: Article

References (25)

1. Cohen A Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987; 1:521-544
2. Propper RD, Cooper B, Rufo RR, Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977; 297:418-423
3. Engle MA, Erlandson M, Smith CH Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30:698-705
4. Wolfe L, Olivieri NF, Sallan D, Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312:1600-1603
5. Brittenham G, Nienhuis AW Desferrioxamine use protects against heart disease and death from transfusional iron overload in thalassemia major. Blood 1988; 72: Suppl: 56a-56a abstract.
6. Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassaemia major. Lancet 1989; 2:27-30
7. Aldouri MA, Wonke B, Hoffbrand AV, High incidence of cardiomyopathy in beta-thalassemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84:113-117
8. Olivieri NF, McGee A, Liu P, Koren G, Freedman MH, Benson L Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous deferoxamine: an update on the Toronto cohort. Ann N Y Acad Sci 1990; 612:585-586
9. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991; 118:540-545
10. Thomas ED, Buckner CD, Sanders JE, Marrow transplantation for thalassaemia. Lancet 1982; 2:227-229
11. Lucarelli G, Galimberti M, Polchi P, Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322:417-421
12. Lucarelli G, Galimberti M, Polchi P, Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329:840-844
13. Simon TL, Sohmer P, Nelson EJ Extended survival of neocytes produced by a new system. Transfusion 1989; 29:221-225
14. Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. Am J Hematol 1992; 41:61-63
15. Addison GM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Pathol 1972; 25:326-329
16. Lerner N, Blei F, Bierman F, Johnson L, Piomelli S Chelation therapy and cardiac status in older patients with thalassemia major. Am J Pediatr Hematol Oncol 1990; 12:56-60
17. Brittenham GM, Cohen AR, McLaren CE, Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81-85
18. Kirkpatrick DV, Barrios NJ, Humbert JH Bone marrow transplantation for sickle cell anemia. Semin Hematol 1991; 28:240-243
19. Welch HG, Larson EB Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321:807-812
20. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JWP Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73:403-409
21. Olivieri NF, Buncic JR, Chew E, Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314:869-873
22. De Virgiliis S, Congia M, Frau F, Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113:661-669
23. Hartkamp MJ, Babyn PS, Olivieri NF Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. Pediatr Radiol 1993; 23:525-528
24. Fosburg MT, Nathan DG Treatment of Cooley's anemia. Blood 1990; 76:435-444
25. Brittenham GM, Farrell DE, Harris JW, Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671-1675